SG Americas Securities
RXRX icon

SG Americas Securities’s Recursion Pharmaceuticals RXRX Stock Holding History

SG Americas Securities’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$945K Buy
257,590
+105,023
+69% +$350K ﹤0.01% 1912
2026
Q1 		$468K Buy
152,567
+77,343
+103% +$299K ﹤0.01% 2219
2025
Q4 		$308K Buy
75,224
+60,523
+412% +$300K ﹤0.01% 2745
2025
Q3 		$72K Sell
14,701
-140,530
-91% -$738K ﹤0.01% 3142
2025
Q2 		$785K Sell
155,231
-6,837
-4% -$33.6K ﹤0.01% 1330
2025
Q1 		$857K Buy
162,068
+112,725
+228% +$822K ﹤0.01% 1302
2024
Q4 		$334K Sell
49,343
-39,982
-45% -$269K ﹤0.01% 1689
2024
Q3 		$589K Buy
89,325
+63,727
+249% +$457K ﹤0.01% 1543
2024
Q2 		$192K Buy
+25,598
New +$223K ﹤0.01% 2184
2024
Q1 		– Sell
-22,186
Closed -$219K – 3378
2023
Q4 		$219K Sell
22,186
-16,741
-43% -$119K ﹤0.01% 2080
2023
Q3 		$298K Buy
38,927
+6,818
+21% +$68K ﹤0.01% 2079
2023
Q2 		$240K Sell
32,109
-22,901
-42% -$160K ﹤0.01% 1728
2023
Q1 		$367K Buy
55,010
+26,988
+96% +$214K ﹤0.01% 1954
2022
Q4 		$216K Buy
28,022
+9,882
+54% +$96.9K ﹤0.01% 2140
2022
Q3 		$193K Buy
18,140
+6,373
+54% +$64.5K ﹤0.01% 2357
2022
Q2 		$96K Buy
+11,767
New +$78.7K ﹤0.01% 3142
2022
Q1 		– Sell
-22,842
Closed -$391K – 3360
2021
Q4 		$391K Buy
22,842
+10,576
+86% +$199K ﹤0.01% 2307
2021
Q3 		$282K Buy
+12,266
New +$348K ﹤0.01% 2994

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

SG Americas Securities's RXRX Position: Q2 2026 in Review

SG Americas Securities increased its Recursion Pharmaceuticals (RXRX) stake by 69% in Q2 2026, buying an estimated $350K and bringing the position to 257,590 shares worth $945K. The position accounts for ﹤0.01% of the portfolio, ranked #1912.

SG Americas Securities first reported a position in RXRX in Q3 2021 and has held it in 18 quarters since. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • SG Americas Securities held 257,590 shares of Recursion Pharmaceuticals worth $945K as of Q2 2026.
  • SG Americas Securities bought 105,023 Recursion Pharmaceuticals shares in Q2 2026, an estimated $350K.
  • Recursion Pharmaceuticals made up ﹤0.01% of SG Americas Securities's portfolio in Q2 2026, its #1912 holding.
  • SG Americas Securities first reported a position in Recursion Pharmaceuticals in Q3 2021 and has held it in 18 quarters since.
  • 342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.